Physician profile
David C Wolf
NPI 1801998950
$305,138.52
in general payments reported to CMS, 2019-2025
16 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $20K · 2021: $25K · 2022: $50K · 2023: $42K · 2024: $40K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Travel and Lodging: $11K · Food and Beverage: $6,768 · Consulting Fee: $3,758 · Honoraria: $1,080 · Education: $9.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,112.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,170.00 |
| Travel and Lodging | $11,375.04 |
| Food and Beverage | $6,768.33 |
| Consulting Fee | $3,757.50 |
| Honoraria | $1,080.00 |
| Education | $9.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $126,145.59 | 2019-2025 | Epclusa, Livdelzi |
| Intercept Pharmaceuticals, INC. | $50,658.75 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $45,803.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $33,188.14 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $21,483.42 | 2022-2023 | Terlivaz |
| Abbvie INC. | $21,229.84 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,404.27 | 2019-2024 | Trulance, Xifaxan |
| Boston Scientific Corporation | $278.53 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.10 | 2019-2022 | |
| Medtronic, INC. | $182.54 | 2025 | Ligasure, Closurefast |
| Capsovision, INC. | $158.25 | 2024 | Capsocam Plus |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Pfizer INC. | $121.41 | 2020 | |
| W. L. Gore & Associates, INC. | $68.44 | 2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Fujifilm Healthcare Americas Corporation | $16.60 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.